Pfizer
ZIRABEV
Manufacturer:
Pfizer
Name:
ZIRABEV
HCPCS Code Descriptor:
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
Category:
Q Code
HCPCS:
Q5118
NDC(s):
00069-0315-01, 00069-0342-01
Primary Type:
Oncology Biosimilar
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
ZIRABEV is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5118 is aligned to the drug ZIRABEV.
Zirabev (bevacizumab) is a VEGF (Vascular Endothelial Growth Factor) protein inhibitor used to treat various types of cancer. This includes colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and certain types of brain tumors, among other types of cancer. Zirabev is manufactured by Pfizer and is biosimilar to Avastin (J9035). This medication is aligned to the HCPCS code Q5118 and has been since October 2019.